Exploratory Study of Tipranavir and Ritonavir in Multiple Protease Inhibitor-experienced HIV Patients
Status:
Completed
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
The primary objective was to evaluate the antiviral activity and safety of two regimens of
tipranavir (500 mg BID or 1000 mg BID) plus ritonavir (100 mg BID) administered in
combination with 1 new nucleoside reverse transcriptase inhibitor (NRTI) + efavirenz in
multiple protease-inhibitor-experienced HIV-1 positive patients.
Phase:
Phase 2
Details
Lead Sponsor:
Boehringer Ingelheim
Treatments:
HIV Protease Inhibitors Protease Inhibitors Reverse Transcriptase Inhibitors Ritonavir Tipranavir